Linking energy sensing to suppression of JAK-STAT signalling: a potential route for repurposing AMPK activators?
Publication date: Available online 13 October 2017 Source:Pharmacological Research Author(s): Claire Speirs, Jamie J.L. Williams, Kirsten Riches, Ian P. Salt, Timothy M. Palmer Exaggerated Janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling is key to the pathogenesis of pro-inflammatory disorders, such as rheumatoid arthritis and cardiovascular diseases. Mutational activation of JAKs is also responsible for several haematological malignancies, including myeloproliferative neoplasms and acute lymphoblastic leukaemia. Accumulating evidence links adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK), an energy sensor and regulator of organismal and cellular metabolism, with the suppression of immune and inflammatory processes. Recent studies have shown that activation of AMPK can limit JAK-STAT-dependent signalling pathways via several mechanisms. These novel findings support AMPK activation as a strategy for management of an array of disorders characterised by hyper-activation of the JAK-STAT pathway. This review discusses the pivotal role of JAK-STAT signalling in a range of disorders and how both established clinically used and novel AMPK activators might be used to treat these conditions. Graphical abstract
Publication date: Available online 10 October 2020Source: Meta GeneAuthor(s): Mansour Zamanpoor, Hamid Ghaedi, Mir Davood Omrani
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Fernando Lopes, Fernando A. Vicentini, Nina L. Cluny, Alexander J. Mathews, Benjamin H. Lee, Wagdi A. Almishri, Lateece Griffin, William Gonçalves, Vanessa Pinho, Derek M. McKay, Simon A. Hirota, Mark G. Swain, Quentin J. Pittman, Keith A. Sharkey
BEST supplements to relieve joint pain: Is your arthritis playing up? The wetter and colder months could partially be to blame. These two pills may help.
Publication date: Available online 9 October 2020Source: Microbiological ResearchAuthor(s): Akhilesh Kumar, Saurabh Singh, Arpan Mukherjee, Rajesh Prasad Rastogi, Jay Prakash Verma
CONCLUSIONS: Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents. PMID: 33034437 [PubMed - as supplied by publisher]
In conclusion, our multidisciplinary approach to prevent de novo hepatitis B is considered useful. PMID: 33028756 [PubMed - in process]
Publication date: 25 February 2021Source: Journal of Alloys and Compounds, Volume 855, Part 1Author(s): Leyuan Li, Yanchen Liu, Haobin Yu, Ruiting Sun, Zhiyu Ding, Kaikai Li, Qunhui Yuan, Junwei Wu, Xingjun Liu
CONCLUSION: Our data suggest that these two polymorphisms do not contribute to AD in the population from the Mersin region of the Eastern Mediterranean. Further studies with larger sample sizes must be conducted to ascertain the association between the 2 polymorphisms. PMID: 33031695 [PubMed - as supplied by publisher]
CONCLUSION: According to our subclinical electrophysiological findings, surgeons that use the posterolateral approach in THA procedures must be conscious of the sciatic nerve's vulnerability to reduce possible clinical complications. PMID: 33031693 [PubMed - as supplied by publisher]
Conclusion: Although treatment algorithms are an attractive tool to guide clinicians and resource allocation, they need to take into account the local population characteristics before routine implementation. Level of Evidence: Level IV–retrospective cohort study.